That's right. In fact, we should have been above $10 following the December data releases and now should be heading to $15, but it apparently was not until the secondary offering that any of the big money guys started to take notice. Plus any definitive news regarding accelerated approval and/or a partnership should take up to the high teens. Although it's hard to chase it here (especially after buying at half the price) it's probably the best value in a development-stage biotech (soon to be commercial going concern) out there right now. As more funds see the potential for gains this year, then even more shareholders will start to get in and they need quite a few shares to move the needle becasue they are so fat. .I think there are still less than 600 individual shareholders and combination of funds of record holding shares- that's a very small number for stock with this much going for it.